Red Lion

Red Lion Biotechnologies is a Swiss-based biopharmaceutical company focused on developing a novel class of immunotherapies and vaccines. The company leverages its proprietary K-Port technology, a specialized delivery platform designed to optimize the administration of therapeutic agents, particularly to the liver. Their primary focus is on oncolytic virus therapies and therapeutic vaccines for the treatment of cancer and infectious diseases. By enhancing the precision of drug delivery, Red Lion aims to improve the efficacy and safety profiles of complex biological treatments. The company is currently advancing its pipeline through pre-clinical stages with a focus on solid tumors.